U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H15ClN2
Molecular Weight 270.757
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEDAZEPAM

SMILES

CN1CCN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3

InChI

InChIKey=YLCXGBZIZBEVPZ-UHFFFAOYSA-N
InChI=1S/C16H15ClN2/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19/h2-8,11H,9-10H2,1H3

HIDE SMILES / InChI

Molecular Formula C16H15ClN2
Molecular Weight 270.757
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Medazepam is a benzodiazepine drug with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is known by the following brand names: Azepamid, Nobrium, Tranquirax (mixed with bevonium), Rudotel, Raporan, Ansilan and Mezapam. Marketed in Russia. Indicated for the treatment of neurotic disorders and states, accompanied with sense of fear, anxiety, intension, raised irritability, insomnia, vegetative lability.

Originator

Curator's Comment: # F. Hoffmann-La Roche Co., Ltd.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Nobrium

Approved Use

This medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety.
Primary
Nobrium

Approved Use

This medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety.
Primary
Nobrium

Approved Use

This medication is used in the treatment of anxiety disorders, alcohol withdrawal, tremor, muscle spasms and to control seizures. It may also be used before surgery or procedures to reduce apprehension and anxiety.
PubMed

PubMed

TitleDatePubMed
Structural requirements of benzodiazepines for the inhibition of pig brain nitric oxide synthase.
2001 Nov 30
Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines.
2002 Apr
[Comprehensive medical and ecological studies in Pryel'brussi].
2003
Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone.
2003 Feb 1
Determination of clofazimine in leprosy patients by high-performance liquid chromatography.
2003 Sep
Mountain sports and total hip arthroplasty: a case report and review of mountaineering with total hip arthroplasty.
2003 Summer
[The nitric oxide system in patients with arterial hypertension living in high mountains].
2007
Cytokinin-binding protein (70 kDa): localization in tissues and cells of etiolated maize seedlings and its putative function.
2007
Separation of 1,4-benzodiazepines by micellar elektrokinetic capillary chromatography.
2007 Jan 10
Human resource management in the Georgian National Immunization Program: a baseline assessment.
2007 Jul 31
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
2008
The educational background and qualifications of UK medical students from ethnic minorities.
2008 Apr 16
Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain.
2008 Aug 19
Benzodiazepine prescription and length of hospital stay at a Japanese university hospital.
2009 Oct 9
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.
2010
Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology.
2010 Aug 1
Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples.
2010 Jan
Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review.
2010 Jun
Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
2010 Mar 15
1-(1-Phenyl-ethyl-idene)carbonohydrazide.
2010 Sep 30
Patents

Sample Use Guides

In Vivo Use Guide
The average dose for adults: single - 10-20 mg, the average daily - 20-30 mg, the maximum - 60-70 mg / day. At the beginning of treatment - for 5 mg 2-3 times a day, then gradually increase the dose to 30-40 mg per day. In outpatient settings recommended by 5 mg in the morning and in the afternoon, and 10 mg in the evening. Elderly patients, teenagers, as well as kidney function - 5-10 mg 1-2 times a day, or 10 mg at night. Babies dose depends on the age and body weight. Treatment duration should be as short as possible (about 2 Sun) and should not exceed 2 Months (including the period of gradual reduction of the dose).
Route of Administration: Oral
In Vitro Use Guide
Medazepam (10 (-5) M) inhibited the contractile response of circular muscle strips from the isolated guinea-pig gallbladder to sulfated cholecystokinin octapeptide (CCK8) in the presence of atropine.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:43:39 GMT 2023
Edited
by admin
on Sat Dec 16 16:43:39 GMT 2023
Record UNII
P0J3387W3S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEDAZEPAM
INN   MART.   MI   WHO-DD  
INN  
Official Name English
medazepam [INN]
Common Name English
MEDAZEPAM [MI]
Common Name English
Medazepam [WHO-DD]
Common Name English
MEDAZEPAM [JAN]
Common Name English
MEDAZEPAM [MART.]
Common Name English
PAMNACE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1012
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
WHO-VATC QN05BA03
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
WHO-ATC N05BA03
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
DEA NO. 2836
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
Code System Code Type Description
EVMPD
SUB08689MIG
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
MESH
D008472
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
MERCK INDEX
m7127
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
220-783-4
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
FDA UNII
P0J3387W3S
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
WIKIPEDIA
MEDAZEPAM
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
PUBCHEM
4041
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL28333
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
NCI_THESAURUS
C66068
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
INN
2517
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
CAS
2898-12-6
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048708
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
SMS_ID
100000081988
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
DRUG BANK
DB13437
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
RXCUI
6680
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
1654
Created by admin on Sat Dec 16 16:43:40 GMT 2023 , Edited by admin on Sat Dec 16 16:43:40 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY